Trial Profile

Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520 by Advanced Tumor Subjects

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rulonilimab (Primary)
Indications Cancer
Focus Adverse reactions
Sponsors Shandong New Time Pharmaceutical Co LTD

Most Recent Events

24 Mar 2020 Planned End Date changed from 8 Oct 2021 to 8 Oct 2022.
24 Mar 2020 Planned primary completion date changed from 8 Feb 2020 to 8 Feb 2021.
15 Apr 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com